Amgen reported first-quarter profit of $1.82 billion, or $3.34 a share, climbing from $1.73 billion, or $3.20 per share, in the prior year. The biotechnology giant's revenue increased 6% to $8.62 billion, surpassing Wall Street's $8.58 billion projection. Strong product sales drove the financial improvement.

Adjusted earnings reached $5.15 per share, exceeding analysts' forecasts of $4.77 per share. The results demonstrate Amgen's ability to outperform market expectations, with both profit and revenue figures exceeding projections. The company's pricing power and product pipeline continue to deliver solid returns.

The performance positions Amgen favorably against biotech peers facing pricing pressures. Investors may view these results as validation of the company's strategic focus on high-value therapeutics. The consistent growth suggests Amgen maintains its competitive edge in the pharmaceutical sector.